• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.260 -0.290 (-11.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 ↗
August 13, 2024
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
August 06, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals's Earnings: A Preview ↗
March 25, 2024
 
Via Benzinga
News headline image
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 28, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 11, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 ↗
May 14, 2024
ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
May 14, 2024
 
Via Benzinga
News headline image
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 08, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 07, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 04, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 ↗
March 26, 2024
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
March 26, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
March 21, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 26, 2024 ↗
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
News headline image
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
March 19, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
March 12, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 08, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
February 21, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
February 01, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot ↗
January 30, 2024
Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding. 
Via InvestorPlace
News headline image
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom ↗
January 24, 2024
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population. 
Via InvestorPlace
News headline image
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap